

Brief review

Cardiac complications of arteriovenous fistulas in patients with end-stage renal disease

Mohamad Alkhouli^{a,*}, Paul Sandhu^b, Khlaed Boobes^c, Kamel Hatahet^d, Farhan Raza^e, Yousef Boobes^f

^a Cardiology Department, University of Rochester, Rochester, NY, USA

^b Department of Internal Medicine, Boston University, Boston, MA, USA

^c Department of Nephrology, Northwestern University, Chicago, IL, USA

^d Department of Nephrology, Temple University Hospital, Philadelphia, PA, USA

^e Cardiology Department, Temple University Hospital, Philadelphia, PA, USA

^f Twam Hospital, Abu Dhabi, United Arab Emirates

ARTICLE INFO

Article history:

Received 28 July 2014

Accepted 23 March 2015

Available online xxx

Keywords:

Hemodialysis vascular access

Cardiovascular

Fistula

Kidney transplantation

ABSTRACT

Cardiovascular disease is the leading cause of the death in dialysis patients. Arteriovenous fistulas (AVFs) are associated with lower mortality and are viewed as the desired access option in most patients with advanced kidney disease needing dialysis. However, AVFs have significant and potentially deleterious effects on cardiac functions particularly in the setting of preexisting heart disease. This article provides a comprehensive and contemporary review to what is known about the impact of AVFs on: congestive heart failure, left ventricular hypertrophy, pulmonary hypertension, right ventricular dysfunction, coronary artery disease and valvular heart disease.

© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Complicaciones cardíacas de las fístulas arteriovenosas en pacientes con enfermedad renal terminal

RESUMEN

La enfermedad cardiovascular es la principal causa de muerte en los pacientes dializados. Las fístulas arteriovenosas (FAV) se asocian a una menor mortalidad y se consideran la opción preferible de vía de acceso en la mayor parte de los pacientes con enfermedad renal avanzada que requieren diálisis. Sin embargo, las FAV tienen efectos importantes y potencialmente nocivos sobre las funciones cardíacas, en especial en presencia de una cardiopatía preexistente. En este artículo se presenta una revisión completa y actualizada de

Palabras clave:

Acceso vascular para hemodiálisis

Cardiovascular

Fístula

Trasplante renal

* Corresponding author.

E-mail addresses: adnanalkhouli@gmail.com, mohamad.alkhouli@urmc.rochester.edu (M. Alkhouli).

<http://dx.doi.org/10.1016/j.nefro.2015.03.001>

2013-2514/© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

los conocimientos existentes sobre las repercusiones que tienen las FAV en los trastornos de: insuficiencia cardiaca congestiva, hipertrofia ventricular izquierda, hipertensión pulmonar, disfunción ventricular derecha, enfermedad coronaria y valvulopatías cardíacas.

© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Cardiovascular disease is the leading cause of the death in patients receiving chronic renal replacement therapy.^{1–3} Arteriovenous fistulas (AVFs) have superior longevity, lower infection and mortality rates and are associated with lower cost, and hence have become the vascular access of choice for patients needing dialysis.⁴ Indeed, the prevalence of AVFs in the United States increased from 32% of all dialysis access in 2003 to 61% in 2012.^{5,6} Despite their association with a lower mortality, AVFs have significant effects on cardiac functions predominantly related to the increase in preload and cardiac output (CO). This article reviews the potential effects of the creation and the ligation of AVFs on cardiac function and their mechanisms.

It should be emphasized, at the outset, that determining the exact effects of AVFs on cardiac functions is fraught with problems for a couple of reasons: patients with end stage renal disease (ESRD) requiring dialysis almost invariably have volume overload due to water and salt retention. They also have pressure load due to arterial sclerosis and hypertension, and increased CO secondary to chronic anemia. In addition, many hemodialysis patients have significant pre-existing myocardial, valvular or coronary heart disease. It is, therefore, often difficult to tease out the exact contribution of an AVF to cardiac dysfunction in hemodialysis patients. Nevertheless, worsening in cardiac functions soon after AVF creation has been observed favoring a causative effect of the AVF on certain cardiac functions. The current literature suggests that the creation of AVF can cause or exacerbate the following conditions: congestive heart failure, left ventricular hypertrophy, pulmonary hypertension, right ventricular dysfunction, coronary artery disease, and valvular dysfunction.

AVFs and congestive heart failure

Congestive heart failure (CHF) is highly prevalent among patients with ESRD. Approximately 35–40% of patients with ESRD have an established CHF diagnosis at initiation of hemodialysis.^{1,3,7–9} Patients with ESRD and CHF have a far worse prognosis than those without CHF.^{3,10} Since hemodynamic optimization is the corner stone of managing patients with ESRD as well as those with CHF, studying the hemodynamic effects of AVFs in patients with ESRD with and without CHF is a sensible task.

Long before we utilized AVFs for hemodialysis access, the hemodynamic effects of AVFs were studied in patients who developed AVFs secondary to trauma AVFs. In these patients, the development of an AVF was noted to be associated with an apparent increase in CO.^{11,12} The introduction of the ‘man-made’ AVFs for hemodialysis access provided more insight into the hemodynamic effects of these fistulas: First, the

creation of an AVF leads to shunting of blood flow from the high resistance arterial system into the low resistance venous system, with a subsequent rise in venous return and CO.¹³ Second, the presence of an AVF decreases arterial impedance and thus lessens the left ventricular afterload. The lowering of arterial impedance may also reduce the effective circulating volume of the systemic circulation, activating arterial baroreceptors, and leading to secondary increase in cardiac sympathetic tone, contractility, and CO.^{14–16} The net effect of AVFs is a significant increase in CO.

Many studies investigated the impact of AVFs on echocardiographic indices of cardiac morphology and function.^{13,14,16–21} These studies consistently showed an increase in LV end-diastolic dimension (LVEDD), contractility, stroke volume and CO within 7–10 days after the surgical construction of AVF.^{13,14,18} Diastolic filling parameters (E to A ratio) were also impaired, indicative of worsening diastolic functions. On average, the creation of an AVF increases CO by 15–20% and left ventricular end-diastolic pressure by 5–10%.¹⁶ Additionally, biomarkers secreted in response to hypervolemia such as atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), are both substantially increased,^{13,14} suggesting the presence of a cardiac volume overload despite an optimal overall body volume status.

The impact of these physiological effects of AVF on the cardiac function is controversial. While many studies suggested that the decreased vascular resistance and the increased CO are predisposing factors for the development or the worsening of heart failure,⁹ others suggested that the decrease in peripheral resistance and blood pressure with a parallel increase in ejection fraction could be potentially beneficial.²²

Risk of worsening heart failure after AVF

There is no standard definition for high output CHF. The literature is inconclusive with regards to the incidence of worsening CHF after AVF creation. Most authors believe that the incidence of high output CHF among hemodialysis patients with AVFs is low, and that most patients with ESRD tolerate AVFs.^{23,24} This belief is supported by the fact that the literature on high output CHF in ESRD patients is limited to case reports and small series^{25–28} and that corrective measures (AVF banding or surgical ligation) due to AVF-related cardiac derangement are uncommon. Dixon et al. noted that the rate of AVF banding due to worsening CHF in a cohort of 204 patients (322 accesses) was only 2.6%.²⁹ On the other hand, some authors suggest that high output CHF is not uncommon but is often overlooked.^{26,30} These authors argue that when cardiac deterioration occur in hemodialysis patients, it is usually attributed to the many risk factors that are highly prevalent in this population, and that the exact contribution of

AVF to the worsening in cardiac functions is often not carefully sought.^{1,3,7–9} This is especially in patients with a long-standing AVFs, although AVF-related worsening CHF has been reported up to 10 years after AVF formation.³¹

It should be emphasized that most ESRD patients tolerate AVF well. However, given the deleterious outcomes in those who do not tolerate AVF, substantial efforts have been made to identify that small fraction of patients who are at risk for cardiac decompensation and high output CHF. There is compelling evidence that the development of high output CHF in ESRD patients with prior clinical or subclinical heart failure, is proportional to the vascular access flow (Qa),^{29,32,33} Most cases of high output CHF were reported in patients with Qa > 2 l/min.³² Upper arm (brachiocephalic) AVFs have twice the flow or lower arm (radiocephalic) AVFs.³⁴ Macrae et al. noted that the average Qa in upper arm AVFs among ESRD patients enrolled in several studies was 1.13–1.72 l/min.³³ In the same cohort, 15% of patients had a Qa > 2 l/min. The ratio of access flow (Qa) to CO can be also be used to predict the risk of worsening CHF. A functional upper arm AVF has an average Qa/CO of 22%. Based on anecdotal experience, high output heart failure was associated with a Qa/CO of >40% in most cases.³³ However, from an epidemiological point of view, high Qa is not clearly associated with an increase in mortality. In an interesting study by Al-Ghonaim et al., there was no increased risk of death at higher levels of Qa.³⁵

Risk of developing de novo heart failure after AVF

Although some authors postulate that cardiac decompensation in ESRD patients with AVFs occurs only in individuals with previously established chronic heart disease, there is evidence that AVF creation is a major risk factor for developing a new onset CHF.^{3,26,33,36} In the HEMO study, symptoms of CHF developed de novo during dialysis therapy in 17% of the patients.³ Albeit this could be purely due to the high prevalence of risk factors for developing CHF in the ESRD population, an independent effect of AVFs has been suggested. In an observational study of 562 pre-dialysis patients, the creation of AVF was more predictive of the development of decompensated CHF than a history of established CHF (odds ratio: 9.54 vs. 2.52, respectively).³⁶ The median time between the creation of the AVF and the first episode of CHF was 51 days (range: 26–138). The location of AVF was, expectantly, closely related to the incidence of new CHF (40% in brachio-cephalic vs. 8% in radiocephalic AVF).

AVFs and left ventricular hypertrophy

Left ventricular (LV) hypertrophy is highly prevalent among patients with ESRD, and is a strong predictor of morbidity and mortality.^{37,38} Although it is mainly a result of chronic systemic hypertension, volume overload and anemia, the presence of an AVF has a non-negligible effect on LV hypertrophy.³⁸ Arteriovenous fistulas increase CO and lead to significant increases in both left ventricular wall mass and diameter in the long-term.^{13,20,39,40} Furthermore, LV hypertrophy tends to persist in patients who had successful kidney transplantation (KT) but have a remaining functional AVF.^{37,38}

Closure of AVFs post-transplant has been shown to be associated with significant regression of LV hypertrophy, despite the observed post-closure increase in both systolic and diastolic blood pressure.^{17,19,41,42} This regression in LV mass starts as early as 3–10 weeks after fistula closure and becomes more pronounced at intermediate and long-term follow up.^{17,42} Although it is intuitive to speculate that regression of LV hypertrophy will lead to fewer cardiovascular events, a direct beneficial effect has not been proven. In fact, some authors believe that the potential benefit of such regression in LV mass after fistula closure might be blunted by the observed shift from a predominately eccentric hypertrophy to a predominantly concentric hypertrophy, a pattern that is known to be associated with worse long term outcomes.^{17,19}

AVFs and pulmonary hypertension

Pulmonary hypertension (PH) complicates ESRD with a prevalence of 12–45%.^{24,43} The presence of PH in the dialysis population confers 2–3 folds increase in all-cause mortality.^{43–45} In the majority of these patients, PH is post-capillary (pulmonary venous hypertension – World Health Organization Class II).⁴⁶ Patients on hemodialysis have several risk factors for developing PH: LV systolic and diastolic dysfunction, volume overload, endothelial dysfunction and sleep-disordered breathing.¹⁵ However, the presence of an AVF has been shown to be an independent risk factor for the development of PH in ESRD patients.^{23,43,47,48} Paneni et al. compared echocardiography-derived peak systolic pulmonary artery pressure (PAP) between patients undergoing peritoneal dialysis (PD), and those receiving hemodialysis with radial and brachial AVFs. Systolic PAP was 29.7 ± 6.7, 37.9 ± 6.7 and 40.8 ± 6.6 mm Hg, respectively ($p < 0.001$).⁴⁷ In concordance with these findings, several other studies found a much less prevalence of PH in patients receiving PD compared to matched cohorts of patients undergoing hemodialysis via AVF.^{23,43,48,49} The mechanisms of AVF-related PH deserve more scrutiny.

The effects of volume overload

As discussed previously, AVFs lead to decreased systemic vascular resistances, increased venous return, and therefore increased pulmonary blood and enhanced CO setting the stage for load-related PH.^{13,14,17,18,20} This theory has been supported by several studies that demonstrated a temporal relationship between PAP rise and AVF creation.^{49–52} These studies also showed a significant association between both the duration of AVF and the fistula flow with the severity of PH.^{49,50,52} Upper arm AVFs, known to have higher flow than lower arm AVFs, are associated with higher risk of developing PH.^{47,50} Compression of the AVFs by a sphygmomanometer,^{43,53} and surgical closure of the AVFs,⁵⁴ both induce a rapid decrease in CO followed by a stable decrease in PAP. The late drop in PAP could be more pronounced than the initial drop when manual compression of an AVF is undertaken. In a case series of five patients in whom manual compression of the AVF in the catheterization laboratory was performed to predict a successful surgical closure, the chronic drop in CO following surgical AVF closure was 4 fold greater

than the fall in CO seen during acute manual compression of the fistula (F. Raza, personal communication). Contrary to these findings, no association between the presence of AVFs or fistula flow and PAP was found in two small studies.^{23,24}

Although AVF-associated volume overload seems to be the prime mechanism in development of PH in the hemodialysis population, the ability of an AVF alone to cause PH has been questioned.⁴³ The pulmonary circuit has an enormous capacity and is usually able to tolerate significant volume loads before it decompensates. Hence, it has been proposed that in patients who develop PH after AVF creation, a baseline pulmonary vascular dysfunction is present leading to failure of the pulmonary circuit to accommodate the AVF-mediated elevated CO.⁴³ This assumption is supported by two observations: (1) Patients without kidney disease or other significant comorbidities are able to tolerate traumatic AVFs for a long time before they develop symptoms of PH or heart failure.^{55–58} (2) Kidney transplantation may revert PAP to normal in patients who still have a functioning AVF.⁵³

Endothelial dysfunction has been suggested as an alternative or additive etiology for the development of pulmonary hypertension in patients with AVF. The vascular endothelium has complex and important physiological functions including controlling the vascular tone.^{59,60} Several studies have shown that patients with ESRD have impaired nitric oxide (NO) production,⁶¹ and increased endothelin-1 (ET-1) activity⁶² both of which have been implicated in the pathophysiology of PH.⁶³ The impaired NO production in dialysis patients is thought to be secondary to the reduced bioavailability of NO substrate L-arginine, and the accumulation of endogenous inhibitors of NO synthase.⁶⁴ The lack of the vasodilator properties of NO could contribute to an increased vascular tone and eventually to the causation of PH. Another potential cause of endothelial dysfunction in dialysis patients is the vascular wall shear stress associated with hemodialysis-related abnormal hemodynamics.^{62,65} In non-dialysis patients with chronic left to right blood shunts (e.g. patients with congenital heart disease), blood shunting augments wall shear stress which leads to endothelial damage, vascular remodeling and PH.^{65,66} Similar effects can be suggested in hemodialysis patients with functional AVFs.^{62,67}

AVFs and right ventricular dysfunction

The prevalence and pathophysiology of PH in patients on hemodialysis has been extensively studied. However, data on the development of right ventricular (RV) dysfunction in ESRD patients with AVF is scarce.

A few recent studies examined the effect of AVFs on echocardiographic parameters of RV dysfunction.^{47,68,69} Paneni et al. studied the prevalence of RV dysfunction in 94 patients on hemodialysis and 26 patients on PD.⁴⁷ In this study, Tissue Doppler-derived myocardial performance index (MPI) was used as an indicator of global RV function. Myocardial performance index has been found to be more sensitive and less load-dependent than other echo indices in predicting RV dysfunction and adverse clinical outcomes.^{70,71} Right ventricular ejection fraction was preserved in the majority

of patients across all subgroups. Right ventricular dysfunction (defined with an MPI > 0.53) was, however, more prevalent in hemodialysis patients compared with PD patients (71.3 vs. 34.6%, $p < 0.001$). The prevalence of RV dysfunction further increased in patients with brachial AVF compared with the radial access (90.6% vs. 61.3%, $p < 0.001$). Logistic regression analysis adjusting for confounding factors including PAP showed that patients carrying AVFs displayed an increased risk of RV dysfunction when compared to the PD group [OR: 6.3 (95% CI: 2.0–19.5), $p < 0.001$]. Again, the risk of RV dysfunction was further enhanced in patients with brachial AVF compared to those with the radial fistulas [OR: 5.9 (95% CI: 1.5–23.1), $p < 0.05$]. In another study of 41 HD patients with AVFs, RV dysfunction (defined by an MPI of > 0.55), was present in 18 patients (44%).⁶⁸ In keeping with the findings by Paneni et al., the presence of AVF was associated with RV dysfunction independent of PAP values. DiLullo et al. also demonstrated that AVFs were associated with impaired RV systolic function (assessed by tricuspid annular plane excursion – TAPSE) and significant RV chamber dilatation compared to those dialyzed via central venous catheters.⁶⁹

The presence of RV dysfunction independent of PAP values, argues against a major role for PH in the development of RV dysfunction in ESRD patients.^{47,68} It also suggests that AVF-dependent volume overload may by itself play a major role in triggering RV dysfunction in patients undergoing hemodialysis.⁴⁷

AVFs and coronary artery disease

Significant coronary artery disease (CAD) is found in 30–40% of ESRD patients on hemodialysis.^{2,9,72} Compared with non-dialysis CAD patients, those on hemodialysis have substantially higher cardiac mortality, and poorer outcomes when undergoing percutaneous or surgical revascularization.^{73,74}

The concern with AVFs in patients with CAD is three-fold: (1) the potential to provoke silent subendocardial myocardial ischemia due to increased oxygen demand and/or decrease oxygen supply. (2) The possible negative impact of AVFs on ipsilateral internal mammary artery (IMA) bypass graft, due to distal steal. (3) The interference of AVFs with cardiopulmonary bypass in patients undergoing coronary artery bypass (CABG) surgery.

Impact of AVF on coronary ischemia

In dog studies, high-flow AVFs were associated with decrease subendocardial coronary perfusion mainly due to decreased diastolic pressure and shortening of the diastolic period.^{75,76} An interesting study by savage et al. used filtered non-fistula arm finger pressure recordings to examine the effects of AVFs on myocardial oxygen supply and demand surrogates.¹⁸ Diastolic pressure time index (DPTI), systolic pressure time index (SPTI), and the DPTI/SPTI ratio were used as indirect measures of myocardial supply, myocardial demand and subendocardial perfusion, respectively. The increase in oxygen demand due to the AVF-related increased CO was ameliorated by the decrease in oxygen demand due to the decreased peripheral vascular resistance caused by the AVF. The net effect on cardiac

oxygen demand was neutral. However, cardiac oxygen supply and, therefore subendocardial perfusion, were both significantly reduced in patients with functioning AVFs. Manual compression of AVFs was associated with improved subendocardial perfusion surrogates.^{18,77} Despite the methodological limitations, these studies suggest a possible negative effect of AVF on subendocardial perfusion. However, confirmatory studies with invasive hemodynamic measurements or advanced imaging tools have not been reported.

Impact of AVF on coronary artery bypass grafting (CABG)

In patients with ESRD who undergo hemodialysis via an upper extremity AVF ipsilateral to the internal mammary artery (IMA) used for CABG, both the bypass graft and the fistula are supplied by the subclavian artery. During hemodialysis, the AVF flow is significant, and can lead to shunting of blood away from the IMA graft (steal phenomenon). There are several reports of symptomatic IMA steal during dialysis session in patients with upper arm (brachio-cephalic) AVFs.^{78,79} Using echocardiography, Gaudino et al. elegantly demonstrated a significant decrease in IMA flow and hypokinesis of the anterior wall of the LV upon initiation of hemodialysis via an ipsilateral AVF in five patients. Both of these findings were reversed when the dialysis machine was turned off.⁸⁰ Conversely, using similar methodology, two studies found that changes in the AVF flow did not significantly alter Doppler flow hemodynamics of either the ipsilateral or contralateral in situ IMA.^{81,82}

The clinical impact of this potential 'steal' phenomenon on clinical outcomes was recently studied.^{83,84} Takami et al. retrospectively compared outcomes of 155 hemodialysis patients whose left anterior descending artery (LAD) was revascularized with the IMA ipsilateral to the AVF (ipsilateral group) and those whose LAD was grafted with the IMA opposite to the fistula (contralateral group).⁸⁴ The overall 5-year survival and cardiac event-free rates were 58% and 74% in the ipsilateral group vs. 65% and 68% in the contralateral group, respectively ($p = 0.90$ and $p = 0.07$). A similar study by Feldman et al. showed comparable survival rates by higher non-fatal cardiac events in the ipsilateral group compared with the contralateral group (81.2% vs. 64%, $p = 0.023$).⁸³ Despite the conflicting evidence, it seems reasonable avoid, when possible, using an IMA coronary artery bypass graft ipsilateral to the AVF. Similarly, placing AVF in a patient with a functioning IMA would be better performed on the contralateral upper extremity.

Another cause for concern in hemodialysis patients with AVFs who are undergoing CABG is the possible interference of AVFs with the integrity of the cardiopulmonary bypass circuit. The excessive venous return to the heart due to high-flow AVFs, can compromise the myocardial protection offered by cardiopulmonary bypass, and lead to impromptu alterations in the surgical plan. In one case, the AVF had to be tied off after CABG to allow successful weaning of cardiopulmonary bypass.⁸⁵ In another case, selective bicaval cannulation was needed to prevent cardiac distention due to the significant left to right shunting of blood via a functional AVF.⁸⁶

AVFs and valvular heart disease

Valvular heart disease is common among patient on hemodialysis with a prevalence of 39–43%.³ The majority of valvular abnormalities (aortic stenosis, aortic regurgitation, mitral regurgitation and tricuspid regurgitation) are sensitive to volume overload. Despite that, data on the effects of AVF-associated volume load on patients with valvular heart disease is limited to patients with aortic stenosis (AS).^{87,88}

Effects of AVF on aortic stenosis

Significant aortic stenosis is present in 3.3% of hemodialysis patients >65 years of age compared with 1–2% in the general population. Also, severe AS is rare in non-ESRD patients who are less than 50 but occurs in 3% of ESRD patients of similar age.⁸⁹

There are two potential effects of AVFs on patients with severe AS: (1) the coexistence of AS and an AVF could complicate the assessment of the severity of aortic valve disease. Cardiac output has significant impact on the assessment of transaortic valve gradient in AS.⁹⁰ In a patient with ESRD and suspected severe AS, manual compression of the AVF dropped the mean transaortic valve gradient from 45 mmHg to 30 mmHg.⁸⁷ (2) The increase in CO associated with the creation of AVF can lead to acute or sub acute decompensation in patients with significant AS who had no symptoms or were minimally symptomatic prior to AVF surgery.⁸⁸

Is closing AVFs beneficial to the heart?

Preserving dialysis access is a priority to both dialysis patients and their physicians. Closing AVFs in patients undergoing hemodialysis has been reserved for those with apparent access failure or apparent access-related complications.²⁹ The management of AVFs in patients who underwent successful KT is a topic of ongoing debate.^{91–93} Most transplant physicians currently suggest that AVF closure is not routinely required in KT recipients with stable renal allograft function.^{91,94} Others believe that AVF closure is associated with significant beneficial effects on cardiac functions and on allograft survival.^{17,19,93,95,96} The benefit of AVF closure should be weighed against the small but the known potential life threatening complications associated with the closure procedure.⁹⁷ A number of studies examined the effects of spontaneous or planned post-KT AVF closure on echocardiographic indices (LV wall mass index, wall thickness, and LVEDD). The potential impact of fistula closure on clinical outcomes was also investigated in a smaller number of studies. A summary of these studies is provided in [Table 1](#).

Effects on echocardiographic parameters

Spontaneous closure of AVFs (due to thrombosis), can result in a significant reduction in CO, LV wall mass index (LVMI), and LVEDD.⁹⁶ Similar benefits were observed in patients who underwent planned surgical AVF closure due to graft

Table 1 – A summary of studies examining the outcomes of spontaneous and planned AVF closure in kidney transplant recipients.

Study	Design	Number of patients	Reason for access closure	Fistula vintage before KT	Follow up	Echocardiographic parameters	Clinical outcomes
Vajdic Trampuz et al. ⁹² 2013	Retrospective single arm (evaluation of complications of functional AVF post-KT)	592 KT patients	NR	42 months	48 months	NR	Complications occurred in 74 patients (12.5%): Painful thrombosis 43.2% Growing aneurysms 27% Venous hypertension 8.1% distal Hypoperfusion 8.1% cardiac failure 8.1% NR
Solaimani et al. ⁹¹ 2012	Retrospective	23 with functional AVF vs. 17 with closed AVF	Spontaneous closure in 34 Planned closure in 4* (out of these patients 17 were included in the study)	30 months	14 months	Patients with closed AVF: significant reduction in IVS (1.16 ± 0.11 vs. 1.10 ± 0.11 cm, $p=0.002$) and PW thickness (1.17 ± 0.11 vs. 1.10 ± 0.11 cm, $p=0.001$) thickness but no significant change in LVEDD (4.87 ± 0.38 vs. 4.85 ± 0.47 cm, $p>0.05$) Patients with persistent AVF: no difference	NR
Głowiński et al. ⁹⁹ 2012	Retrospective case-controlled	9 matched pairs	Spontaneous closure in 4 planned closure in 5 for cosmetic reasons	24 months	11 months	No significant difference after AVF closure in IVS and PW thickness, LVEDD, LVWMI in both groups	NR
Kurita et al. ⁵⁰ 2011	Retrospective single arm	30 functional AVF and 3 with functional grafts	Planned closure due to refractory heart failure	36 months	60 months	No significant difference after AVF closure in IVS and PW thickness, LVEDD, LVWMI	70% had symptomatic improvement (responders). Responders had better early survival but 5-years survival was similar in both groups

Table 1 – (Continued)

Study	Design	Number of patients	Reason for access closure	Fistula vintage before KT	Follow up	Echocardiographic parameters	Clinical outcomes
Movilli et al. ¹⁷ 2010	Prospective observational	35 with functional AVF and 25 with closed AVF	Planned closure due to malfunction	56 months	6 months	Patients with closed AVF: significant reduction in IVS and PW thickness (11.8 ± 2.1 vs. 11.0 ± 2.2 cm, and 10.8 ± 1.7 vs. 10.0 ± 1.9 cm, <i>p</i> < 0.001). LVEDD and LVWMI also significantly decreased (51 ± 4 vs. 49 ± 4 and 135 ± 40 vs. 123 ± 23 g/m ²). <i>p</i> < 0.001 for all. Patients with persistent AVF: no difference NR	NR
Vajdic et al. ⁹³ 2010	Retrospective (evaluation of effects of persistent AVF on allografts after KT)	239 with functional AVF and 72 with closed AVF	Spontaneous closure in 70 planned closure in 2*	NR	70 months	NR	5 years allograft survival was 60% in patients with persistent AVF vs. 75% in those with closed AVF (<i>p</i> = 0.045). Persistent AVF was an independent risk factor for allograft loss (HR 1.336; 95% CI, 1.018–1.755; <i>p</i> = 0.037) NR
Cridlig et al. ⁹⁶ 2008	Retrospective case–controlled	38 matched pairs	Spontaneous closure in 23 Planned closure in 4* Previously closed in 11 (9 on PD, 2 with tunneled catheters)	23 months	65 months	Compared with those with closed AVF, patients with persistent AVF had: more PW thickness (12.2 ± 1.7 vs. 11.5 ± 1.8 cm, <i>p</i> = 0.007), larger LVEDD (52.1 ± 7.1 vs. 48.5 ± 6.0, <i>p</i> = 0.02), and higher LVMI (135.1 ± 30.3 vs. 112.4 ± 28 g/m ² , <i>p</i> = 0.001).	
Sheashaa et al. ⁹⁸ 2004	Prospective observational	34 with functional AVF and 17 with closed AVF	Spontaneous closure in all	17 months	12 months, echo 120 months, clinical	No difference in IVS and PW thickness, LVEDD, and LVMI between the two groups	No significant difference in death or allograft survival between the two groups

Table 1 – (Continued)

Study	Design	Number of patients	Reason for access closure	Fistula vintage before KT	Follow up	Echocardiographic parameters	Clinical outcomes
Unger et al. ¹⁹ 2004	Prospective observational	8 with functional AVF and 17 with closed AVF	Planned closure for CHF (n = 10), venous hypertension (n = 6), and/or cosmetic reasons (n = 5)	88 months	32 months	Patients with closed AVF: significant reduction in LVEDD (29.5 ± 3.4 vs. 26.2 ± 3.2 mm, p = 0.017) and LVWMI 139 ± 44 to 117 ± 40 g/m ² , p < 0.001) at 21 months. No significant difference in IVS and PW thickness.	NR
VanDuijnhoven et al. ⁹² 2001	Prospective interventional	22 with functional AVF	Planned closures in all ** (excluded CHF patients)	104 months	46 months	Patients with persistent AVF: no difference After 3 months of AVF closure: Both LVEDD and LVWMI decreased: (51.5 ± 5.8 vs. 49 ± 5.4 mm, p < 0.01) and (135 ± 34 vs. 119.8 ± 23 g/m ² , p < 0.01), respectively. No significant difference in IVS and PW thickness.	NR
Delima et al. ²¹ 1999	Retrospective	39 with functional AVF and 22 with closed AVF	Planned closure for cosmetic reasons within 2 months of KT in all	62 months, group I 36 months, group II	14 months	Compared with those with closed AVF, patients with persistent AVF had higher LVEDD (52.7 ± 4.8 vs. 49.2 ± 4.6, p = 0.007). No significant difference in IVS or PW thickness and LVWMI.	NR

dysfunction,¹⁷ cardiovascular derangements,¹⁹ or as part of a research protocol.⁴¹ Contrary to these findings, other studies found no significant effects of spontaneous or planned AVF closure on echocardiographic indices.^{21,91,94,98}

Effects on clinical outcomes

In a large cohort of patients who underwent KT, the incidence of AVF-related complications requiring an intervention was 12.5% at 4 years.⁹² In these patients, cardiac decompensation and distal arm hypoperfusion constituted 16.2% of all complications. Transplant allograft survival was positively affected by AVF closure in one study,⁹³ but was not different in another.⁹⁸ In all-comers, AVF closure was not associated with a mortality benefit at 10 years.⁹⁸ Only one study explored the effects of AVF closure on clinical outcomes in patients with refractory heart failure.⁹⁵ In this study 30 patients with AVF and 3 with arteriovenous grafts were referred for access closure due to refractory CHF. There was an immediate significant improvement in CHF symptoms in 70% of patients (responders), but no benefit was seen in the other 30% (non-responders). The non-responders had higher prevalence of ischemic heart disease and longer durations since their AVF creation. Those who responded had better survival at 1 year, but had similar mortality rates as the non-responders at 5 years.

Conclusion

There are currently near 400,000 patients on hemodialysis and 180,000 kidney transplant recipients in the United States.⁶ The majorities of these patients have cardiovascular disease and have functional AVFs.^{1,2,5} Arteriovenous fistulas are associated with lower mortality and are viewed as the desired access option in most patients with ESRD needing dialysis.⁴ Arteriovenous fistulas are well tolerated by most patients. However, the potentially deleterious effects of AVFs, particularly in the setting of preexisting heart disease should not be underestimated. A multidisciplinary evaluation of patients with known heart disease before AVF creation is warranted. Additionally, in patients who develop dyspnea, heart failure, or pulmonary hypertension, AVF revision should be considered as an important therapeutic option, especially in those who underwent successful kidney transplantation.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. *Am J Kidney Dis.* 2000;36:S24–30.
- Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. *Lancet.* 2000;356:147–52.
- Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. *Kidney Int.* 2004;65:2380–9.
- Lok CE. Fistula first initiative: advantages and pitfalls. *Clin J Am Soc Nephrol.* 2007;2:1043–53.
- Fistula First Catheter Data. Incident vascular access and nephrology care prior to initiation of treatment. <http://fistulafirst.org/AboutFistulaFirst/FistulaFirstCatheterLastFFCLData.aspx> [accessed 10.06.14].
- Incident & prevalent ESRD patient counts 2012. United States Renal Data System. <http://www.usrds.org/2012/view/v2.01.aspx> [accessed 08.06.14].
- Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. *Am J Kidney Dis.* 2001;38:992–1000.
- Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. *Kidney Int.* 1995;47:884–90.
- Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. *Semin Dial.* 2003;16:101–5.
- Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. *J Am Soc Nephrol.* 1999;10:1606–15.
- Cohen SM, Edholm OG. Cardiac output and peripheral blood flow in arteriovenous aneurysm. *Clin Sci (Lond).* 1948;7:35–47.
- Warren JV, Elkin DC, Nickerson JL. The blood volume in patients with arteriovenous fistulas. *J Clin Invest.* 1951;30:220–6.
- Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. *Am J Kidney Dis.* 2002;40:974–82.
- Ori Y, Korzets A, Katz M, Perek Y, Zahavi I, Gaftor U. Haemodialysis arteriovenous access – a prospective haemodynamic evaluation. *Nephrol Dial Transplant.* 1996;11:94–7.
- Bolignano D, Rastelli S, Agarwal R, Fliser D, Massy Z, Ortiz A, et al. Pulmonary hypertension in CKD. *Am J Kidney Dis.* 2013;61:612–22.
- London GM. Left ventricular alterations and end-stage renal disease. *Nephrol Dial Transplant.* 2002;17 Suppl. 1: 29–36.
- Movilli E, Viola BF, Brunori G, Gaggia P, Camerini C, Zubani R, et al. Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: a prospective study. *Am J Kidney Dis.* 2010;55:682–9.
- Savage MT, Ferro CJ, Sassano A, Tomson CR. The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: a prospective study. *Am J Kidney Dis.* 2002;40:753–9.
- Unger P, Velez-Roa S, Wissing KM, Hoang AD, van de Borne P. Regression of left ventricular hypertrophy after arteriovenous fistula closure in renal transplant recipients: a long-term follow-up. *Am J Transplant.* 2004;4:2038–44.
- Wijnen E, Keuter XH, Planken NR, van der Sande FM, Tordoir JH, Leunissen KM, et al. The relation between vascular access flow and different types of vascular access with systemic hemodynamics in hemodialysis patients. *Artif Organs.* 2005;29:960–4.
- De Lima JJ, Vieira ML, Molnar LJ, Medeiros CJ, Ianhez LE, Krieger EM. Cardiac effects of persistent hemodialysis arteriovenous access in recipients of renal allograft. *Cardiology.* 1999;92:236–9.
- Korsheed S, Eldehni MT, John SG, Fluck RJ, McIntyre CW. Effects of arteriovenous fistula formation on arterial stiffness

- and cardiovascular performance and function. *Nephrol Dial Transplant*. 2011;26:3296-302.
23. Unal A, Tasdemir K, Oymak S, Duran M, Kocyigit I, Oguz F, et al. The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. *Hemodial Int*. 2010;14:398-402.
 24. Acarturk G, Albayrak R, Melek M, Yuksel S, Usulan I, Atli H, et al. The relationship between arteriovenous fistula blood flow rate and pulmonary artery pressure in hemodialysis patients. *Int Urol Nephrol*. 2008;40:509-13.
 25. Bailey WB, Talley JD. High-output cardiac failure related to hemodialysis arteriovenous fistula. *J Ark Med Soc*. 2000;96:340-1.
 26. Engelberts I, Tordoir JH, Boon ES, Schreij G. High-output cardiac failure due to excessive shunting in a hemodialysis access fistula: an easily overlooked diagnosis. *Am J Nephrol*. 1995;15:323-6.
 27. Dikow R, Schwenger V, Zeier M, Ritz E. Do AV fistulas contribute to cardiac mortality in hemodialysis patients? *Semin Dial*. 2002;15:14-7.
 28. Young PR Jr, Rohr MS, Marterre WF Jr. High-output cardiac failure secondary to a brachiocephalic arteriovenous hemodialysis fistula: two cases. *Am Surg*. 1998;64:239-41.
 29. Dixon BS, Novak L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. *Am J Kidney Dis*. 2002;39:92-101.
 30. MacRae JM, Levin A, Belenkie I. The cardiovascular effects of arteriovenous fistulas in chronic kidney disease: a cause for concern? *Semin Dial*. 2006;19:349-52.
 31. Anderson CB, Codd JR, Graff RA, Groce MA, Harter HR, Newton WT. Cardiac failure and upper extremity arteriovenous dialysis fistulas. Case reports and a review of the literature. *Arch Intern Med*. 1976;136:292-7.
 32. Basile C, Lomonte C, Vernaglione L, Casucci F, Antonelli M, Losurdo N. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. *Nephrol Dial Transplant*. 2008;23:282-7.
 33. MacRae JM, Pandeya S, Humen DP, Krivitski N, Lindsay RM. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. *Am J Kidney Dis*. 2004;43:e17-22.
 34. Begin V, Ethier J, Dumont M, Leblanc M. Prospective evaluation of the intra-access flow of recently created native arteriovenous fistulae. *Am J Kidney Dis*. 2002;40:1277-82.
 35. Al-Ghonaïm M, Manns BJ, Hirsch DJ, Gao Z, Tonelli M, Alberta Kidney Disease N. Relation between access blood flow and mortality in chronic hemodialysis patients. *Clin J Am Soc Nephrol*. 2008;3:387-91.
 36. Martinez-Gallardo R, Ferreira-Morong F, Garcia-Pino G, Cerezo-Arias I, Hernandez-Gallego R, Caravaca F. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. *Nefrologia*. 2012;32:206-12.
 37. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. *J Am Soc Nephrol*. 2003;14:462-8.
 38. Parfrey PS, Harnett JD, Griffiths SM, Taylor R, Hand J, King A, et al. The clinical course of left ventricular hypertrophy in dialysis patients. *Nephron*. 1990;55:114-20.
 39. Hiremath S, Doucette SP, Richardson R, Chan K, Burns K, Zimmerman D. Left ventricular growth after 1 year of haemodialysis does not correlate with arteriovenous access flow: a prospective cohort study. *Nephrol Dial Transplant*. 2010;25:2656-61.
 40. Ori Y, Korzets A, Katz M, Erman A, Weinstein T, Malachi T, et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. *Am J Kidney Dis*. 2002;40:745-52.
 41. van Duijnhoven EC, Cheriex EC, Tordoir JH, Kooman JP, van Hooff JP. Effect of closure of the arteriovenous fistula on left ventricular dimensions in renal transplant patients. *Nephrol Dial Transplant*. 2001;16:368-72.
 42. Unger P, Wissing KM, de Pauw L, Neubauer J, van de Borne P. Reduction of left ventricular diameter and mass after surgical arteriovenous fistula closure in renal transplant recipients. *Transplantation*. 2002;74:73-9.
 43. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. *Chest*. 2003;123:1577-82.
 44. Ramasubbu K, Deswal A, Herdejurgan C, Aguilar D, Frost AE. A prospective echocardiographic evaluation of pulmonary hypertension in chronic hemodialysis patients in the United States: prevalence and clinical significance. *Int J Gen Med*. 2010;3:279-86.
 45. Li Z, Liu S, Liang X, Wang W, Fei H, Hu P, et al. Pulmonary hypertension as an independent predictor of cardiovascular mortality and events in hemodialysis patients. *Int Urol Nephrol*. 2014;46:141-9.
 46. Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Grohe C, Nickenig G, et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. *PLoS ONE*. 2012;7:e35310.
 47. Paneni F, Gregori M, Ciavarella GM, Sciarretta S, De Biase L, Marino L, et al. Right ventricular dysfunction in patients with end-stage renal disease. *Am J Nephrol*. 2010;32:432-8.
 48. Bozbas SS, Akcay S, Altin C, Bozbas H, Karacaglar E, Kanyilmaz S, et al. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. *Transplant Proc*. 2009;41:2753-6.
 49. Fabbian F, Cantelli S, Molino C, Pala M, Longhini C, Portaluppi F. Pulmonary hypertension in dialysis patients: a cross-sectional Italian study. *Int J Nephrol*. 2011;2011:283475.
 50. Abdelwhab S, Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. *Am J Nephrol*. 2008;28:990-7.
 51. Dagli CE, Sayarlioglu H, Dogan E, Acar G, Demirpolat G, Ozer A, et al. Prevalence of and factors affecting pulmonary hypertension in hemodialysis patients. *Respiration*. 2009;78:411-5.
 52. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, et al. Pulmonary hypertension in patients with chronic renal failure. *Respiration*. 2007;74:503-10.
 53. Nakhoul F, Yigla M, Gilman R, Reisner SA, Abassi Z. The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. *Nephrol Dial Transplant*. 2005;20:1686-92.
 54. Clarkson MR, Giblin L, Brown A, Little D, Donohoe J. Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula. *Am J Kidney Dis*. 2002;40:E8.
 55. Spencer TA, Smyth SH, Wittich G, Hunter GC. Delayed presentation of traumatic aortocaval fistula: a report of two cases and a review of the associated compensatory hemodynamic and structural changes. *J Vasc Surg*. 2006;43:836-40.
 56. Schneider M, Creutzig A, Alexander K. Untreated arteriovenous fistula after World War II trauma. *Vasa*. 1996;25:174-9.
 57. Lesaux N, Paulhac P, Bouillet P, Plainard X, Colombeau P, Dumas JP. Post-traumatic renal arteriovenous fistula discovered after 28 years. *Prog Urol*. 2005;15:306-8.
 58. Chaudry M, Flinn WR, Kim K, Neschis DG. Traumatic arteriovenous fistula 52 years after injury. *J Vasc Surg*. 2010;51:1265-7.
 59. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. *Nephrol Dial Transplant*. 2000;15:1194-200.

60. Cross J. Endothelial dysfunction in uraemia. *Blood Purif.* 2002;20:459-61.
61. Vaziri ND. Effect of chronic renal failure on nitric oxide metabolism. *Am J Kidney Dis.* 2001;38:S74-9.
62. Yigla M, Keidar Z, Safadi I, Tov N, Reisner SA, Nakhoul F. Pulmonary calcification in hemodialysis patients: correlation with pulmonary artery pressure values. *Kidney Int.* 2004;66:806-10.
63. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. *Am J Med Sci.* 2000;320:223-32.
64. Okubo K, Hayashi K, Wakino S, Matsuda H, Kubota E, Honda M, et al. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension. *Hypertens Res.* 2005;28:181-9.
65. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. *Prog Cardiovasc Dis.* 2002;45:173-202.
66. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. First of two parts. *N Engl J Med.* 2000;342:256-63.
67. Abassi Z, Nakhoul F, Khankin E, Reisner SA, Yigla M. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. *Curr Opin Nephrol Hypertens.* 2006;15:353-60.
68. Said K, Hassan M, Baligh E, Zayed B, Sorour K. Ventricular function in patients with end-stage renal disease starting dialysis therapy: a tissue Doppler imaging study. *Echocardiography.* 2012;29:1054-9.
69. Di Lullo L, Floccari F, Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. *Nephron Clin Pract.* 2011;118:c257-61.
70. Arinc H, Gunduz H, Tamer A, Ozhan H, Akdemir R, Saglam H, et al. Use of tissue Doppler to assess right ventricle function in hemodialysis patients. *Am J Nephrol.* 2005;25:256-61.
71. Miller D, Farah MG, Liner A, Fox K, Schluchter M, Hoit BD. The relation between quantitative right ventricular ejection fraction and indices of tricuspid annular motion and myocardial performance. *J Am Soc Echocardiogr.* 2004;17:443-7.
72. Jungers P, Nguyen Khoa T, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. *Nephrol Dial Transplant.* 1999;14:898-902.
73. Papafaklis MI, Naka KK, Papamichael ND, Kolios G, Sioros L, Sclerou V, et al. The impact of renal function on the long-term clinical course of patients who underwent percutaneous coronary intervention. *Catheter Cardiovasc Interv.* 2007;69:189-97.
74. Cooper WA, O'Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, et al. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: results from the Society of Thoracic Surgeons National Adult Cardiac Database. *Circulation.* 2006;113:1063-70.
75. Buckberg GD, Fixler DE, Archie JP, Henney RP, Hoffman JI. Variable effects of heart rate on phasic and regional left ventricular muscle blood flow in anesthetized dogs. *Cardiovasc Res.* 1975;9:1-11.
76. Buckberg GD, Fixler DE, Archie JP, Hoffman JI. Experimental subendocardial ischemia in dogs with normal coronary arteries. *Circ Res.* 1972;30:67-81.
77. Bos WJ, Zietse R, Wesseling KH, Westerhof N. Effects of arteriovenous fistulas on cardiac oxygen supply and demand. *Kidney Int.* 1999;55:2049-53.
78. Kato H, Ikawa S, Hayashi A, Yokoyama K. Internal mammary artery steal in a dialysis patient. *Ann Thorac Surg.* 2003;75:270-1.
79. Crowley SD, Butterly DW, Peter RH, Schwab SJ. Coronary steal from a left internal mammary artery coronary bypass graft by a left upper extremity arteriovenous hemodialysis fistula. *Am J Kidney Dis.* 2002;40:852-5.
80. Gaudino M, Serricchio M, Luciani N, Giungi S, Salica A, Pola R, et al. Risks of using internal thoracic artery grafts in patients in chronic hemodialysis via upper extremity arteriovenous fistula. *Circulation.* 2003;107:2653-5.
81. Rahbar R, McGee WR, Birdas TJ, Muluk S, Magovern J, Maher T. Upper extremity arteriovenous fistulas induce modest hemodynamic effect on the in situ internal thoracic artery. *Ann Thorac Surg.* 2006;81:145-7.
82. Tokuda Y, Song MH. Internal thoracic artery grafts and upper extremity arteriovenous fistula. *Ann Thorac Surg.* 2007;84:2138.
83. Feldman L, Tkacheva I, Efrati S, Rabin I, Beberashvili I, Gorelik O, et al. Effect of arteriovenous hemodialysis shunt location on cardiac events in patients having coronary artery bypass using an internal thoracic artery. *ther Apher Dial.* 2014;18:450-4.
84. Takami Y, Tajima K, Kato W, Fujii K, Hibino M, Munakata H, et al. Effects of the side of arteriovenous fistula on outcomes after coronary artery bypass surgery in hemodialysis-dependent patients. *J Thorac Cardiovasc Surg.* 2014;147:619-24.
85. Nyawo B, Pawale A, Pardeshi L, Talbot D, Forty J. The effect of a large proximal haemodialysis arterio-venous fistula on weaning off cardiopulmonary bypass: case report. *J Cardiothorac Surg.* 2008;3:44.
86. Cetin L, Sener E, Kunt A, Hidiroglu M, Kucuker A. Impact of a large hemodialysis arteriovenous fistula: on myocardial protection during cardiopulmonary bypass. *Tex Heart Inst J.* 2012;39:122-4.
87. Ennezat PV, Marechaux S, Pibarot P. From excessive high-flow, high-gradient to paradoxical low-flow, low-gradient aortic valve stenosis: hemodialysis arteriovenous fistula model. *Cardiology.* 2010;116:70-2.
88. Alkhouli M, Alasfar S, Samuels LA. Valvular heart disease and dialysis access: a case of cardiac decompensation after fistula creation. *J Vasc Access.* 2013;14:96.
89. Umana E, Ahmed W, Alpert MA. Valvular and perivalvular abnormalities in end-stage renal disease. *Am J Med Sci.* 2003;325:237-42.
90. Carabello BA, Paulus WJ. Aortic stenosis. *Lancet.* 2009;373:956-66.
91. Soleimani MJ, Shahrokh H, Shadpour P, Shirani M, Arasteh S. Impact of dialysis access fistula on cardiac function after kidney transplantation. *Iran J Kidney Dis.* 2012;6:198-202.
92. Vajdic Trampuz B, Ponikvar R, Kandus A, Buturovic-Ponikvar J. Hemodialysis arteriovenous fistula-related complications and surgery in kidney graft recipients. *Ther Apher Dial.* 2013;17:444-7.
93. Vajdic B, Arnol M, Ponikvar R, Kandus A, Buturovic-Ponikvar J. Functional status of hemodialysis arteriovenous fistula in kidney transplant recipients as a predictor of allograft function and survival. *Transplant Proc.* 2010;42:4006-9.
94. Glowinski J, Malyszko J, Glowinska I, Mysliwiec M. To close or not to close: fistula ligation and cardiac function in kidney allograft recipients. *Pol Arch Med Wewn.* 2012;122:348-52.
95. Kurita N, Mise N, Tanaka S, Tanaka M, Sai K, Nishi T, et al. Arteriovenous access closure in hemodialysis patients with refractory heart failure: a single center experience. *Ther Apher Dial.* 2011;15:195-202.
96. Cridlig J, Selton-Suty C, Alla F, Chodek A, Pruna A, Kessler M, et al. Cardiac impact of the arteriovenous fistula after kidney transplantation: a case-controlled, match-paired study. *Transplant Int.* 2008;21:948-54.
97. Pascual J, Martins J, Bouarich H, Galeano C, Barrios V, Marcen R, et al. Sudden death after arteriovenous fistula ligation in a renal transplant patient. *Ann Vasc Surg.* 2008;22:134-5.

-
98. Sheashaa H, Hassan N, Osman Y, Sabry A, Sobh M. Effect of spontaneous closure of arteriovenous fistula access on cardiac structure and function in renal transplant patients. *Am J Nephrol*. 2004;24:432–7.
99. Głowiński J, Małyszko J, Głowińska I, Myśliwiec M. To close or not to close: fistula ligation and cardiac function in kidney allograft recipients. *Pol Arch Med Wewn*. 2012;122:348–52.